J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.

Hand man doing finances and calculate on desk about cost at home office.

More from Drug Pricing

More from Scrip